Journal info
|
||
Select Journal
Journals
Bratislava Medical Journal Endocrine Regulations General Physiology and Biophysics Neoplasma 2024 Ahead of print 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.
Neoplasma Vol.63, No.5, p.816-821,2016 |
||
| Title: The impact of p16 and HER2 expression on survival in patients with ovarian carcinoma | ||
| Author: F. H. SHANDIZ, S. KADKHODAYAN, K. GHAFFARZADEGAN, H. ESMAEILY, S. TORABI, S. A. KHALES | ||
| Abstract: The purpose of this study was to investigate the impact of p16 and HER2 expression on survival in patients with ovarian carcinoma. This descriptive-analytic, cross-sectional study, was conducted on 47 paraffin blocks of epithelial ovarian tumors. Suitable slides were prepared to evaluate HER2 and p16 by immunohistochemistry using HercepTest kit (DAKO) and p16INK4A kit (DAKO, code 5334). Clinical information and pathology data were extracted from patients’ medical and pathology records. Data entry and analysis was done by SPSS (version 16) software. Chi-square test, Mann-Whitney test, t-test, Kruskal-Wallis test, log rank test and Kaplan-Meier method were used. The mean age of the patients was 51.6 years (range 19-71 years). The most common histological type of epithelial ovarian cancer was serous adenocarcinoma (68.1%). P16 expression was detected in 34% of epithelial ovarian tumors. P16 expression was significantly associated with stage of disease (P = 0.04) and overall survival (P = 0.001), but HER2 expression was not associated with overall survival, stage of disease and tumor histological type. Expression of p16 may be used as a prognostic factor of overall survival and stage of disease, while HER2 expression may not be used as a prognostic factor of overall survival. |
||
| Keywords: p16, HER2/neu, immunohistochemistry, epithelial ovarian tumors | ||
| Published online: 09-Sep-2016 | ||
| Year: 2016, Volume: 63, Issue: 5 | Page From: 816, Page To: 821 | |
| doi:10.4149/neo_2016_520 |
||
|
|
 download file |
|